NHD Global
Growth Hormone & IGF · Ghrelin-receptor agonist research
Scientific Product Dossier
Ipamorelin is a peptide ghrelin-receptor agonist and growth-hormone secretagogue. In a 117-patient randomized postoperative-ileus trial, median time to a tolerated meal was 25.3 versus 32.6 hours, but the primary comparison was not statistically significant (p=0.15). FDA identifies route-specific safety-information, immunogenicity and peptide-characterization gaps.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
117 enrolled; 114 analyzed. Median time to a tolerated meal was 25.3 versus 32.6 hours, p=0.15.
Intravenous inpatient protocol after bowel resection; cannot be generalized to other routes.
Read the primary studyFDA flags immunogenicity, aggregation/impurity and unnatural-amino-acid characterization concerns, with insufficient safety data for some routes.
FDA assessment describes evidence gaps, not a test of this catalog lot.
Read the primary studyFive infusion-rate levels were studied with eight healthy men at each level. The reported terminal half-life was about 2 hours; GH peaked at approximately 0.67 hours.
This was an intravenous pharmacokinetic study, not a trial of long-term body-composition outcomes. Subcutaneous kinetics cannot be assumed from these results.
Read the primary study117 patients were enrolled and 114 entered the safety and modified intention-to-treat populations. Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15).
The primary and secondary efficacy analyses did not show significant between-group differences. The study concerned hospital patients after bowel resection.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Beck DE, et al. International Journal of Colorectal Disease. 2014. PMID 25331030.
View primary recordU.S. FDA current ipamorelin summary.
View primary recordThird-party publications selected for direct relevance.
Beck DE, et al. International Journal of Colorectal Disease. 2014. PMID 25331030.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
No. The 25.3 versus 32.6 hour median comparison had p=0.15.
No. Exposure route, clinical setting and formulation are part of the evidence and cannot be transferred automatically.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Ipamorelin was tested in a multicenter, double-blind, placebo-controlled bowel-resection study. The median result numerically favored ipamorelin, but the difference was not statistically significant and…
Updated August 28, 2026
Ipamorelin evidence is route- and protocol-specific. FDA’s current review notes immunogenicity and impurity concerns, unnatural amino-acid characterization complexity and insufficient safety information for some…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: IP2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
